Rare cancers account for ~25–30% of all cancer diagnoses and 25% of cancer deaths, representing a substantial burden of disease. However, basic science research, clinical trials and approval of new therapies for rare cancers are lacking. This translates into a worse prognosis for patients with a rare cancer than for those with common cancers. With the number of rare cancers increasing, finding more appropriate solutions for diagnosing, managing and studying rare cancers is essential.
Please check the details for first one here and the second one here or on ...
Congratulations to our RCG team member Alexandra Sexton-Oates who won 2nd place in both of ...
We are delighted to welcome back Laurane Mangé as a PhD student in the team, ...
Rare Cancer Genomics
NETRF 2022
RCG Initiative 2020